健康なボランティアおよびピーナッツアレルギー患者におけるMY006の安全性、薬物動態、および薬力学的効果を評価する研究
健康なボランティアおよびピーナッツアレルギーの思春期および成人患者におけるMY006の安全性、局所耐容性、薬物動態、免疫原性、薬力学、および探索的臨床活性を評価するための無作為化、四重盲検、プラセボ対照、単回漸増および反復投与試験
The goal of this clinical trial is to evaluate the safety, pharmacokinetics, and effectiveness of MY006, a therapy designed to prevent severe or potentially life-threatening allergic reactions caused by accidental peanut intake. In the first part of the study, adult participants receive one dose or two doses of MY006 or a placebo, administered by subcutaneous injection. The safety of MY006, including the number of adverse events, injection-site reactions, and immunogenicity, in these participants will be reviewed by an independent Safety Monitoring Committee and, if the safety is judged acceptable, the second part of the study will be started. In the second part of the study, adult and adolescent participants with peanut allergy receive one dose of MY006 or a placebo, administered by subcutaneous injection. Several weeks later, the participants are given a food peanut challenge to assess reactions and treatment effects. The duration of the study for participants is for up to 31 weeks.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
Arkansas
-
Little Rock、Arkansas、アメリカ、72202
- 募集
- Arkansas Children's Hospital and Research Institute
-
コンタクト:
- Erin Thomas
- 電話番号:501-364-2325
- メール:thomases@archildrens.org
-
-
Colorado
-
Aurora、Colorado、アメリカ、80045
- 募集
- Children's Hospital Colorado
-
コンタクト:
- David Fleischer
- 電話番号:720-777-2575
- メール:David.Fleischer@childrenscolorado.org
-
Colorado Springs、Colorado、アメリカ、809907
- 募集
- Asthma and Allergy Associates, PC
-
コンタクト:
- Kavya Muthyala
- 電話番号:719-473-8330
- メール:Kmuthyala@aacos.com
-
-
Florida
-
Miami、Florida、アメリカ、33136
- 積極的、募集していない
- Syneos Health Clinical Research Services LLC
-
Tampa、Florida、アメリカ、33613
- 募集
- University of South Florida
-
コンタクト:
- Catherine Smith
- 電話番号:813-631-4024
- メール:catherinesmith@usf.edu
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02114
- 募集
- Massachusetts General Hospital
-
コンタクト:
- Brianna Fountain
- 電話番号:617-643-6772
- メール:blfountain@mgh.harvard.edu
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48105
- 募集
- Mary H. Weiser Food Allergy Center (MHWFAC) University of Michigan - Michigan Medicine
-
コンタクト:
- Ian Slack
- 電話番号:734-615-2592
- メール:Foodallergytrials@med.umich.edu
-
-
Texas
-
Dallas、Texas、アメリカ、75235
- 募集
- Children's Health
-
コンタクト:
- Ruby Thapa
- 電話番号:214-648-0258
- メール:ruby.thapa@utsouthwestern.edu
-
Houston、Texas、アメリカ、77030
- 募集
- Texas Children's Hospital/Baylor College of Medicine
-
コンタクト:
- Daisy Vita
- 電話番号:832-824-3640
- メール:Dxtran1@texaschildrens.org
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key Inclusion Criteria:
Part A - Single-ascending dose and multiple dose cohorts in healthy volunteers
- Subject is male or female between 18 to 55 years of age, inclusive, at the screening visit.
- Subject agrees voluntarily to participate, and is able to read and understand, and willing to sign, the Institutional Review Board/Independent Ethics Committee-approved informed consent form prior to performing any screening visit procedures.
- Subject weight at screening and admission is between 45 kg and 100 kg, inclusive.
- Subject has a body mass index between 18.0 and 30.0 kg/m2, inclusive, at screening visit.
Part B - Peanut-allergic patient cohorts
-
Participant and/or parent/legal guardian must be able to understand and provide informed consent and/or assent, as applicable.
-
Patient is male or female between 12 to 55 years of age, inclusive, at the screening visit.
-
Patient weight at screening and admission is between 40 kg and 100 kg, inclusive.
-
If patient is 12-17 years of age, their body mass index (BMI) must be above the 5th percentile and below the 95th percentile for age and sex at the screening visit. If patient is 18 years of age or above, their BMI must be between 18.0 and 30.0 kg/m2, inclusive, at the screening visit.
-
Patient has a history of allergy to peanut and meets all of the following criteria:
- Positive skin prick test (≥5 mm wheal greater than Placebo) to peanut; and
- Positive specific IgE (≥0.7 kUA/L) to peanut and Ara h 2 at screening determined by ImmunoCap; and
- Positive double-blinded challenge to peanut during the screening period, defined as experiencing dose-limiting symptoms at a single dose of ≤300 mg of peanut protein.
-
Patient is willing and able to avoid peanut-containing products and any other allergy-inducing foods known to the patient for the duration of study participation.
Key Exclusion Criteria:
Part A - Single-ascending dose and multiple dose cohorts in healthy volunteers
-
Subject has a clinically relevant history, as determined by the Principal Investigator or designee, or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, and/or connective tissue diseases or disorders.
-
Subject has clinically significant abnormal vital signs, after 5 minutes or more of sitting rest, defined as any of the following:
- Systolic blood pressure ≥140 mmHg;
- Diastolic blood pressure ≥90 mmHg; and/or
- Heart rate ≥90 beats per minute.
-
Subject has any clinically significant abnormalities in rhythm, conduction, or morphology of the resting electrocardiogram (ECG) and/or any clinically significant abnormalities in the 12-lead ECG as considered by the Principal Investigator or designee that may interfere with the interpretation of QTc interval changes.
-
Subject has history of severe allergy/hypersensitivity, ongoing clinically significant allergy/hypersensitivity, as judged by the Principal Investigator or designee, known or suspected allergy to peanuts, and/or history of hypersensitivity to drugs with a similar structure or class.
Part B - Peanut-allergy patient cohorts
-
Patient has history of frequent or recent severe, life-threatening episodes of anaphylaxis or anaphylactic shock to peanut, as defined by more than 3 episodes of anaphylaxis within the past year and/or an episode of anaphylaxis within 60 days of screening.
-
Patient has uncontrolled or severe asthma/wheezing at screening, defined by one or more of the following criteria:
- Global Initiative for Asthma criteria regarding asthma control per latest guidelines;
- History of two or more systemic corticosteroid courses within 6 months of screening or one course of systemic corticosteroids within three months of screening to treat asthma/wheezing;
- Prior intubation/mechanical ventilation for asthma/wheezing;
- One hospitalization or emergency department visit for asthma/wheezing within 12 months of screening;
- Inhaled corticosteroid (ICS) dosing of >500 mcg daily fluticasone (or equivalent ICS based on the CoFAR Inhaled Corticosteroid Equivalency Tables); and/or
- Forced expiratory volume in one second (FEV1) <75% of predicted or FEV1/forced vital capacity <75%, with or without controller medications.
-
Patient has unstable exacerbated atopic disease (e.g., atopic dermatitis, urticaria, allergic rhinitis) defined by an episode of disease requiring initiation of systemic immunosuppressive or immunomodulatory treatment in the last 3 months.
-
Patient has current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal, or metabolic dysfunction unless currently controlled and stable as judged by the Principal Investigator.
-
Patient has abnormal vital signs, after 5 minutes or more of sitting rest, defined as any of the following:
- Systolic blood pressure ≥140 mmHg;
- Diastolic blood pressure ≥90 mmHg; and/or
- Heart rate ≥90 beats per minute.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:順次割り当て
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Part A, Single Ascending Dose, Dose Level 1 (Healthy Volunteers)
Cohort A1: MY006 or Placebo, subcutaneous, single dose in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
MY006 administered by subcutaneous injection. Placebo (vehicle) administered by subcutaneous injection. |
|
実験的:Part A, Single Ascending Dose, Dose Level 2 (Healthy Volunteers)
Cohort A2: MY006 or Placebo, subcutaneous, single dose in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
Placebo (vehicle) administered by subcutaneous injection. MY006 administered by subcutaneous injection. |
|
実験的:Part A, Single Ascending Dose, Dose Level 3 (Healthy Volunteers)
Cohort A3: MY006 or Placebo, subcutaneous, single dose in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
Placebo (vehicle) administered by subcutaneous injection. MY006 administered by subcutaneous injection. |
|
実験的:Part A, Multiple Dose (Healthy Volunteers)
Cohort A4: MY006 or Placebo, subcutaneous, every 2 weeks, total of 2 doses in healthy volunteers. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
Placebo (vehicle) administered by subcutaneous injection. MY006 administered by subcutaneous injection. |
|
実験的:Part B, Single Dose with Early Peanut Challenge (Peanut-Allergic Patients)
Cohort B1: MY006 or Placebo, subcutaneous, single dose in adults and adolescents. Peanut challenge will occur early after dosing. The cohort will consist of 8 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
Placebo (vehicle) administered by subcutaneous injection. MY006 administered by subcutaneous injection. |
|
実験的:Part B, Single Dose with Late Peanut Challenges (Peanut-Allergic Patients)
Cohort B2: MY006 or Placebo, subcutaneous, single dose in adults and adolescents. Peanut challenge will occur late after dosing. The cohort will consist of up to 16 subjects. The subjects will be randomized in a 6:2 ratio in a quadruple-blinded manner to receive MY006 or Placebo (vehicle), respectively. |
Placebo (vehicle) administered by subcutaneous injection. MY006 administered by subcutaneous injection. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Subjects with Adverse Events and Serious Adverse Events (Safety and Local Tolerability)
時間枠:From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
The nature of the adverse event (AE), date of the AE onset, date of the AE outcome to date, severity of the AE, and action taken for the AE will be documented together with the Principal Investigator's assessment of the seriousness of the AE and causal relationship to study drug and/or study procedure. The AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 21.0 or higher. |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pharmacokinetics: Cmax (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Maximum serum MY006 concentration in cohorts of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
|
Pharmacokinetics: Tmax (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Time to reach Cmax of MY006 in cohorts of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
|
Pharmacokinetics: AUClast (Part A, SAD, Cohorts A1-A3)
時間枠:From dosing (Day 1) to End of Study visit (Week 24)
|
Area under the concentration-time curve (AUC) from Pre-Dose (time 0) to the time of the last quantifiable concentration (tlast) in single ascending dose (SAD) cohorts of adult healthy volunteers (Part A) |
From dosing (Day 1) to End of Study visit (Week 24)
|
|
Pharmacokinetics: AUClast (Part A, MD, Cohort A4)
時間枠:From Day 15 to End of Study visit (Week 26)
|
AUC from Pre-Dose on Day 15 (time 0) to the time of the last quantifiable concentration (tlast) following last dose in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From Day 15 to End of Study visit (Week 26)
|
|
Pharmacokinetics: AUC0-504hr (Part A, SAD, Cohorts A1-A3)
時間枠:From dosing (Day 1) to Day 21
|
AUC from Pre-Dose (time 0) to 504 hours post-dosing in single ascending dose (SAD) cohorts of adult healthy volunteers (Part A) |
From dosing (Day 1) to Day 21
|
|
Pharmacokinetics: AUC0-336hr (Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to Day 14
|
AUC from Pre-Dose (time 0) to 336 hours postdosing in peanut-allergic patients (Part B) |
From dosing (Day 1) to Day 14
|
|
Pharmacokinetics: AUC0-336hr (Part A, MD, Cohort A4)
時間枠:From dosing (Day 1) to Day 14
|
AUC from Pre-Dose (time 0) to 336 hours post-dosing in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From dosing (Day 1) to Day 14
|
|
Pharmacokinetics: AUCinf (Part A, SAD, Cohorts A1-A3; Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to End of Study visit (Week 24)
|
AUC from Pre-Dose (time 0) extrapolated to infinite time in single ascending dose (SAD) cohorts of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Week 24)
|
|
Pharmacokinetics: AUCinf (Part A, MD, Cohort A4)
時間枠:From Day 15 to End of Study visit (Week 26)
|
AUC from Pre-Dose on Day 15 (time 0) extrapolated to infinite time in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From Day 15 to End of Study visit (Week 26)
|
|
Pharmacokinetics: AUC%extrap (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to End of Study visit (Part A, Week 24 or Week 26; Part B, Week 24)
|
Percentage of AUCinf that is due to extrapolation beyond tlast in cohorts of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or Week 26; Part B, Week 24)
|
|
Pharmacokinetics: λz (Part A, MD, Cohort A4; Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to End of Study visit (Week 24)
|
Terminal elimination rate constant in multiple dose (MD) cohort of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Week 24)
|
|
Pharmacokinetics: t½ (Part A, MD, Cohort A4; Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to End of Study visit (Part A, Week 26; Part B, Week 24)
|
Terminal elimination half-life in multiple dose (MD) cohort of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Part A, Week 26; Part B, Week 24)
|
|
Pharmacokinetics: CL/F (Part A, MD; Cohort A4, Day 15; Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to Day 15 (Part A) or End of Study visit (Part B, Week 24)
|
Total body clearance in multiple dose (MD) cohort of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to Day 15 (Part A) or End of Study visit (Part B, Week 24)
|
|
Pharmacokinetics: Vz/F (Part A, MD, Cohort A4, Day 15; Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to End of Study visit (Part A, Week 26; Part B, Week 24)
|
Apparent volume of distribution in multiple dose (MD) cohort of adult healthy volunteers (Part A) and peanut-allergic patients (Part B) |
From dosing (Day 1) to End of Study visit (Part A, Week 26; Part B, Week 24)
|
|
Pharmacokinetics: Racc,Cmax (Part A, MD, Cohort A4)
時間枠:From dosing (Day 1) to Day 15
|
Ratio of last dose Cmax (Day 15) to first dose Cmax (Day 1) in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From dosing (Day 1) to Day 15
|
|
Pharmacokinetics: Racc,C72 (Part A; MD; Cohort A4)
時間枠:From dosing (Day 1) to Day 18
|
Ratio of MY006 concentration at 72 hours (C72) post Day 15 to first dose C72 (Day 1) in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From dosing (Day 1) to Day 18
|
|
Pharmacokinetics: Racc,C168 (Part A, MD, Cohort A4)
時間枠:From Day 8 to Day 22
|
Ratio of MY006 concentration at 168 hours (C168) post Day 15 dose to first dose C168 (Day 1) in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From Day 8 to Day 22
|
|
Pharmacokinetics: Racc,AUC0-336hr (Part A, MD, Cohort A4)
時間枠:From dosing (Day 1) to Day 15
|
Ratio of last dose AUC0-336hr (Day 15) to first dose AUC0-336hr (Day 1) in multiple dose (MD) cohort of adult healthy volunteers (Part A) |
From dosing (Day 1) to Day 15
|
|
Immunogenicity: ADA (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Percentage of subjects developing treatment-emergent anti-drug antibodies (ADA) |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
|
Immunogenicity: Treatment-enhanced ADA (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Percentage of subjects developing treatment-enhanced ADA |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
|
Immunogenicity: ADA Titers (Part A, Cohorts A1-A4; Part B, Cohorts B1-B2)
時間枠:From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
Amount of ADA in subjects |
From dosing (Day 1) to End of Study visit (Part A, Week 24 or 26; Part B, Week 24)
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
その他の研究ID番号
- MY-CLN-SP-006-PA1001
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。